Standard indemnification agreement with the Company.
| Officer | Age | In this role | Joined | 2025 pay | Source |
|---|---|---|---|---|---|
|
Scott A. Smith
Also a director
Chief Executive Officer
Title from the Form 4 dated Mar 6, 2026
|
63 | Not stated | Not stated | $15,273,331 | |
|
Matthew Maletta
Chief Legal Officer
|
Not stated |
Since 2026
this year
|
Not stated | Not reported | |
|
Goff Corinne Le
Chief Commercial Officer
Title from the Form 4 dated Apr 15, 2026
|
Not stated | Not stated | Not stated | $5,934,898 | |
|
Paul Campbell
See Remarks
Title from the Form 4 dated Jun 25, 2026
|
Not stated | Not stated | 2002 | Not reported | |
|
Andrew Enrietti
See Remarks
Title from the Form 4 dated Aug 15, 2026
|
Not stated | Not stated | Not stated | $4,303,062 |
Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.
Standard indemnification agreement with the Company.
Company payments to counsel to Mr. Malik for services in connection with previously disclosed drug pricing matters.
Anticipated additional Company payments to counsel to Mr. Malik for ongoing services in connection with drug pricing matters.
Company payment to Mr. Malik relating to profit sharing contributions and prior participation in the 401(k) Restoration Plan.
Extension of Mr. Malik's advisory role to March 31, 2026 on current terms providing continued vesting of his equity awards; 261,490 PRSUs vested during the extended period.
Loading...